Skip to main content
. Author manuscript; available in PMC: 2022 Oct 28.
Published in final edited form as: Cell. 2021 Oct 28;184(22):5593–5607.e18. doi: 10.1016/j.cell.2021.09.035

Figure 2. Differential requirements for the Fc regions of mAbs rEBOV-442 and rEBOV-515 for optimal therapeutic protection in mice.

Figure 2.

C57BL/6 mice were challenged with EBOV-MA (day 0), treated at 1 dpi with wild-type IgG1 or IgG1 LALA-PG variant of mAbs rEBOV-442 (5 mg/kg) and rEBOV-515 (1 mg/kg), and monitored for 28 days. Antibodies ADI-15946 IgG1 (1 mg/kg) and ADI-15878 IgG1 (5 mg/kg) were included for comparative purposes, and mAb rDENV 2D22 was used as a control. (A) Kaplan-Meier survival plot. The overall difference in survival between the groups was estimated using two-sided log-rank (Mantel–Cox) test.

(B) Weight change. A historical control for protection from weight loss with 5 mg/kg of hybridoma-produced mAb EBOV-515 treatment (Gilchuk et al., 2018a) is indicated with a raspberry dotted line.

(C) Clinical score.

Mean values are shown in (B-C). For the rEBOV-515 and rEBOV-442 treatment groups a total of n=10 mice per group was analyzed in two independent experiments, for which cumulative data are shown. For the ADI-15946 and ADI-15878 treatment groups, data represent one experiment with 5 mice per group. Body-weight-change and clinical score data in (B-C) are shown only for the animals that survived at each indicated time point. Timepoints for mAb treatment are indicated with dotted vertical lines